Related articles
Case Study: Medable, CRO, & pharma partner to accelerate clinical trial deployment at scale
A top-3 contract research organization (CRO) and a top-10 pharmaceutical company partnered with Medable to help accelerate the speed, scale, and standardization of their eCOA trials.
The two organizations had been hampered by lengthy configuration timelines, inconsistent designs across studies, and siloed processes between sponsors and their CRO partners.
By centralizing the sponsor’s preferred instruments and configurations into a reusable digital library, Medable enabled the CRO to rapidly accelerate its portfolio development and initiate new studies without starting them “from scratch.”
Complete the form to get your copy of the case study and see how we enable rapid acceleration for CROs.
Drive scale with total control: Medable's new CRO partner program
What does it mean to do the heavy lifting?
In clinical research, it means assisting with research and development of new drugs alongside pharmaceutical and biotechnology companies, helping them complete the routine work that turns the gears to make new medicines.
Within pharma, contract research organizations (CROs) are indispensable partners in the advancement of clinical research who manage the complexities of clinical trials from protocol design to regulatory closeout, handling tasks like trial design, patient recruitment, data management, and regulatory submissions.
As a result, CROs have become indispensable partners in the advancement of clinical research who significantly contribute to our industry’s development of groundbreaking treatments, and human health.
However, the weights and the lifting methods have been changing. As Boston Consulting Group noted in their 2024 Nature article, clinical trials are becoming more complex. As a result, CROs face increasing pressure to deliver more with less.
Recognizing their importance in our mission and vision, Medable is excited to announce the launch of our comprehensive CRO partner program, designed to be a game-changing engine for growth and control in the clinical research industry.
What happened at ASCO 2025?
2025’s American Society of Clinical Oncology (ASCO) meeting in Chicago once again delivered a wealth of clinical data, providing exciting insights into the groundbreaking future of cancer treatment. As the show closed out, we checked in with our associates to see what they thought were the biggest news and trends of the show.